Rein Therapeutics

Rein Therapeutics is advancing a novel pipeline of first-in-class medicines to address unmet medical needs in orphan pulmonary and fibrosis indications.

[Rein Therapeutics @Rein_Tx]

@WebullGlobal https://t.co/e2vpf0NnnK?

[Rein Therapeutics @Rein_Tx]

Interested in learning more about $RNTX?

Join CEO Brian Windsor today (June 24) at 2pm ET on @WebullGlobal's Biotech Webinar Series for an overview of Rein Therapeutics, our Phase 2 IPF program, recent milestones, and what's ahead.

Registration link in comments below.

[Rein Therapeutics @Rein_Tx]

Our CEO, Brian Windsor, is back on the road again.

Patients with IPF don’t get a break. So neither do we.

No one ever said that putting an end to fibrosis was going to be easy!

$RNTX

[Rein Therapeutics @Rein_Tx]

https://t.co/PODekFMeBv

[Rein Therapeutics @Rein_Tx]

Phase 2 RENEW trial update:

• First patient enrolled in the UK
• 16 patients enrolled to date
• Active enrollment now underway in 3 countries

We continue to expand the global footprint of the study as we advance LTI-03 in IPF.

$RNTX

[Rein Therapeutics @Rein_Tx]

We successfully closed our previously announced financing, including the full exercise of the underwriters’ over-allotment option, increasing total gross proceeds to $ 57.5M.

The transaction consisted solely of common stock, with no warrants or other derivatives.

Watch our CEO Brian Windsor discuss what this means for the Company and our ongoing Phase 2 RENEW trial in #IPF.

$RNTX

[Rein Therapeutics @Rein_Tx]

Two important updates:
• We’re raming up our Phase 2 RENEW trial of LTI-03 in #IPF
• We just completed a $50m financing
CEO Brian Windsor breaks it down in this video...

$RNTX

[Rein Therapeutics @Rein_Tx]

Why is the company called Rein Therapeutics?

Our name reflects both our Texas roots and our mission: To rein in fibrosis, a devastating lung disease that still has limited treatment options.

CEO Brian Windsor explains the story...

#IPF #PulmonaryFibrosis

$RNTX

@AustinEconDev
@austinlocalbiz_

[Rein Therapeutics @Rein_Tx]

We dosed the first patient in our Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF)!

Following recent FDA clearance, this randomized, placebo-controlled study will enroll ~120 patients to evaluate safety and potential impact on lung function.

Quick recap from CEO Brian Windsor here.

Looking forward to reporting interim data ~ 2H 2026.

#IPF #PulmonaryFibrosis $RNTX

[Rein Therapeutics @Rein_Tx]

Rein’s pipeline goes beyond a single drug or a single disease.

In this video, CEO Brian Windsor explains how our Cav1 peptide platform, starting with LTI-03 in IPF, could have broader applications across fibrotic diseases that affect multiple organs. It's a market that could exceed $10B globally.

🎥 Watch the video to learn more!

$RNTX

[Rein Therapeutics @Rein_Tx]

2026 could be a pivotal year for $RNTX.

In this video, CEO Brian Windsor explains why our Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis (#IPF) matters, and how we’re working to preserve lung function for patients who urgently need better options.

🎥 Watch here!

[Rein Therapeutics @Rein_Tx]

https://t.co/0NMb85gMHk

[Rein Therapeutics @Rein_Tx]

Pleased to announce that we received orphan drug designation from the European Medicines Agency for LTI-03 in idiopathic pulmonary fibrosis (IPF).

The designation recognizes the significant unmet need in #IPF and supports our plans to restart our Phase 2 program and advance European clinical development.

Press release link in comments.

$RNTX

[Rein Therapeutics @Rein_Tx]

Most IPF programs target a single pathway. We believe that’s not enough for a disease this complex.

🎥 Watch our CEO, Brian Windsor, explain why Rein is taking a multi-pathway approach with LTI-03. We're aiming to rebalance #fibrosis biology and support the lung’s ability to heal.

$RNTX #PulmonaryFibrosis #IPF

[Rein Therapeutics @Rein_Tx]

Fibrosis represents one of the largest untapped opportunities in medicine. It's a market that could exceed $10B by 2032.

Our CEO Brian Windsor breaks down why #IPF is our first focus, how LTI-03 aims to go beyond slowing disease, and how our Cav1 peptide platform could extend far beyond the lungs.

🎥 Watch here!

$RNTX #Fibrosis

[Rein Therapeutics @Rein_Tx]

IPF is a $4B+ disease with outcomes worse than many cancers, yet it rarely gets the attention it deserves.

Our CEO Brian Windsor breaks down what #IPF actually is, why it’s so devastating, and why the need for better treatments is so urgent.

🎥 Watch here!

$RNTX #IPF #PulmonaryFibrosis #Fibrosis

[Rein Therapeutics @Rein_Tx]

Interview here: https://t.co/tigeYkFsZ0

[Rein Therapeutics @Rein_Tx]

Thanks to Stockhouse for inviting our CEO, Brian Windsor, on their WatchList show. Always grateful for the opportunity to tell our story!

Link to interview in comments below.

$RNTX

[Rein Therapeutics @Rein_Tx]

Science can get complicated fast, especially with conditions like idiopathic pulmonary fibrosis (IPF).
We want to make the basics clearer for everyone - patients, families and investors.

🎥 Here, our CEO Brian Windsor breaks down what “pulmonary” and “fibrosis” actually mean, why lung scarring becomes dangerous, and how it affects everyday life.

$RNTX #PulmonaryFibrosis #IPF #Fibrosis